成都艾迪医药技术

Chengdu Aidi Pharmaceutical Technology is a research and development-focused subsidiary of Jiangsu Aidi Pharmaceutical, specializing in the discovery of innovative small molecule drugs. The company primarily targets infectious diseases, with a significant emphasis on HIV/AIDS treatments, as well as oncology and inflammatory conditions. Its flagship product, Ainuovirine (ACC007), is a domestically developed non-nucleoside reverse transcriptase inhibitor that has received marketing approval in China. Additionally, the company has successfully launched Ainuomicitabine (ACC008), a triple-combination single-tablet regimen for HIV-1. Chengdu Aidi serves as a critical innovation hub within the Aidi Pharma group, leveraging its technical expertise to advance a diverse pipeline of clinical-stage candidates. The company is committed to addressing unmet medical needs in the Chinese market through the development of high-quality, accessible antiviral therapies.